Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021
February 26, 2021 11:39 ET
|
Ehave
MIAMI, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced plans to launch...
Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Technology is Expected to Provide Continuous Monitoring
February 17, 2021 08:30 ET
|
Ehave
Ehave, Inc. to leverage data and AI to correlate biomarkers for the identification of psychedelic drug administration as a treatment for Chronic pain, Depression (major and persistent), PTSD, Bipolar...
Ehave Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression
February 01, 2021 08:30 ET
|
Ehave
MIAMI, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, is announcing plans to roll...
Ehave Looks to Expand KetaDASH to Palliative Care
January 27, 2021 08:30 ET
|
Ehave
MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it is...
Ehave, Inc. Utilizes Artificial Intelligence and Machine Learning for Big Data Management in Mental Healthcare
January 25, 2021 08:30 ET
|
Ehave
MIAMI, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to...
Ehave Closes Transaction to Acquire CureDash Assets, Adds KetaDASH Home Delivery Service for Ketamine Clinics
January 22, 2021 08:30 ET
|
Ehave
MIAMI, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it completed...
Ehave Revolutionizes Patient Medical Records for Psychedelic Mental Health
January 21, 2021 08:51 ET
|
Ehave
Medical records platform for psychedelic mental health to be available February 1 as a Plugin to the Ehave Dashboard. MIAMI, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the...
Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector
January 20, 2021 08:30 ET
|
Ehave
MIAMI, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced today the Company has closed the transaction to sell 100% of its...
Ehave Forms Partnership with Cognitive Apps to Introduce Revolutionary AI Voice Assistant That Will Revolutionize Mental Health in Psychedelic Sector
January 11, 2021 08:30 ET
|
Ehave
MIAMI, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced it has licensed revolutionary AI to unlock the human voice as a...
Ehave, Inc. Partners with Cognitive Apps to Add Artificial Intelligence-Powered Mental Health Analytical Platform for Psychedelic Use in G20 Countries
January 07, 2021 08:30 ET
|
Ehave
MIAMI, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics, announced today the Company has signed a partnership agreement with...